All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00085183" target="_blank" >RIV/00216224:14110/15:00085183 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11130/15:10315984 RIV/65269705:_____/15:00063644 RIV/00843989:_____/15:E0105143 RIV/00064203:_____/15:10315984

  • Result on the web

    <a href="http://dx.doi.org/10.1097/MBC.0000000000000298" target="_blank" >http://dx.doi.org/10.1097/MBC.0000000000000298</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1097/MBC.0000000000000298" target="_blank" >10.1097/MBC.0000000000000298</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003

  • Original language description

    Our objective was to assess the incidence of inhibitors development in Czech Republic since the introduction of recombinant factor VIII (rFVIII) and to look for the factors potentially influencing this parameter. It is to be expected that inhibitors riskmay be increased after the introduction of recombinant products. Data of Czech National Haemophilia Programme registry entered from 2003 till 2013 were analysed. Both annual and absolute incidences of newly developed inhibitors in previously untreated patients (PUPs) were calculated. Bleeding and treatment data were also extracted, and association to the treatment regimen and development of inhibitors were analysed. Within the given period, we commenced 45 PUPs with haemophilia A on rFVIII and treatedthem for 137 treatment-years. Twenty-two of the PUPs had severe haemophilia A, being treated for 88 treatment-years. Treatment strategy for them was prophylaxis. Other PUPs were treated on demand.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

    <a href="/en/project/EE2.4.12.0048" target="_blank" >EE2.4.12.0048: Hemophilia centres</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2015

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Blood Coagulation and Fibrinolysis

  • ISSN

    0957-5235

  • e-ISSN

  • Volume of the periodical

    26

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    6

  • Pages from-to

    673-678

  • UT code for WoS article

    000364400500013

  • EID of the result in the Scopus database